These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30814828)

  • 1. Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice.
    Lai JML; Yang SL; Avoi R
    J Glob Infect Dis; 2019; 11(1):2-6. PubMed ID: 30814828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    Al-Shaer MH; Mansour H; Elewa H; Salameh P; Iqbal F
    BMC Infect Dis; 2017 Feb; 17(1):118. PubMed ID: 28152986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
    Al-Shaer MH; Elewa H; Alkabab Y; Nazer LH; Heysell SK
    BMC Infect Dis; 2018 Aug; 18(1):384. PubMed ID: 30089476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
    Aseffa A; Chukwu JN; Vahedi M; Aguwa EN; Bedru A; Mebrahtu T; Ezechi OC; Yimer G; Yamuah LK; Medhin G; Connolly C; Rida W; Aderaye G; Zumla AI; Onyebujoh PC;
    PLoS One; 2016; 11(6):e0157434. PubMed ID: 27322164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Tolerability of Risorine with Conventional Rifampicin in the Treatment of Newly Diagnosed Pulmonary Tuberculosis Patients.
    Patel N; Jagannath K; Vora A; Patel M; Patel A
    J Assoc Physicians India; 2017 Sep; 65(9):48-54. PubMed ID: 29313577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
    Lienhardt C; Cook SV; Burgos M; Yorke-Edwards V; Rigouts L; Anyo G; Kim SJ; Jindani A; Enarson DA; Nunn AJ;
    JAMA; 2011 Apr; 305(14):1415-23. PubMed ID: 21486974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.
    Gallardo CR; Rigau Comas D; Valderrama Rodríguez A; Roqué i Figuls M; Parker LA; Caylà J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD009913. PubMed ID: 27186634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.
    Braga JU; Trajman A
    BMC Infect Dis; 2015 Feb; 15():81. PubMed ID: 25879615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
    Bartacek A; Schütt D; Panosch B; Borek M;
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):760-6. PubMed ID: 19460254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampin with bio-enhancer in the treatment of newly diagnosed sputum positive pulmonary tuberculosis patients: A double-center study.
    Nageswari AD; Rajanandh MG; Uday MKRA; Nasreen RJ; Pujitha RR; Prathiksha G
    J Clin Tuberc Other Mycobact Dis; 2018 Aug; 12():73-77. PubMed ID: 31720402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S; Mannava MKC; Nangia A
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.